abbv-383
abbvie
#ims2022 | peter voorhees shares the fih results of the bcma-directed #bispecific antibody abbv-383 (tnb-383b). administered every 3 weeks, this new agent achieves an orr &gt;50% in the subgroups studied, including triple-refractory #mmsm 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma